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Abstract
Background: Accurately characterizing a drug’s safety profile is essential. Trial harm and tolerability assessments
rely, in part, on participants’ reports of medical histories, adverse events (AEs), and concomitant medications.
Optimal methods for questioning participants are unclear, but different methods giving different results can
undermine meta-analyses. This study compared methods for eliciting such data and explored reasons for dissimilar
participant responses.
Methods: Participants from open-label antimalarial and antiretroviral interaction trials in two distinct sites (South
Africa, n = 18 [all HIV positive]; Tanzania, n = 80 [86% HIV positive]) were asked about ill health and treatment use by
sequential use of (1) general enquiries without reference to particular conditions, body systems or treatments, (2)
checklists of potential health issues and treatments, (3) in-depth interviews. Participants’ experiences of illness and
treatment and their reporting behaviour were explored qualitatively, as were trial clinicians’ experiences with obtaining
participant reports. Outcomes were the number and nature of data by questioning method, themes from qualitative
analyses and a theoretical interpretation of participants’ experiences.
Results: There was an overall cumulative increase in the number of reports from general enquiry through checklists to
in-depth interview; in South Africa, an additional 12 medical histories, 21 AEs and 27 medications; in Tanzania an
additional 260 medical histories, 1 AE and 11 medications. Checklists and interviews facilitated recognition of health
issues and treatments, and consideration of what to report. Information was sometimes not reported because
participants forgot, it was considered irrelevant or insignificant, or they feared reporting. Some medicine names were
not known and answers to questions were considered inferior to blood tests for detecting ill health. South African
inpatient volunteers exhibited a “trial citizenship”, working to achieve researchers’ goals, while Tanzanian outpatients
sometimes deferred responsibility for identifying items to report to trial clinicians.
Conclusions: Questioning methods and trial contexts influence the detection of adverse events, medical histories and
concomitant medications. There should be further methodological work to investigate these influences and find
appropriate questioning methods.
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Background
Assessments of drug harm and tolerability rely, in part,
on clinical trial participant reports of adverse events
(AEs), medical histories and concomitant medications.
However, there is no consensus regarding the detail of
how such reports should be elicited, in particular how
participants should be questioned about ill health and
their use of medications other than the study drug(s).
Heterogeneity in elicitation methods provides potential
for measurement error if questioning methods are sub-
optimal, and undermines meta-analyses of adverse ef-
fects [1,2]. Staff may use general enquiries to identify
AEs, such as ‘How have you been feeling?’, yet the im-
pact of variation in phraseology between or within trials
is unclear [3]. Some trials elicit responses using detailed,
structured approaches like symptom lists, often aimed at
ascertaining anticipated adverse effects or AEs of special
interest, though detection of unanticipated effects may
remain unsystematic [4,5]. Questioning may also involve
self-completed forms or diaries. There is evidence that
more detailed elicitation techniques increase the sensi-
tivity of participant-reported AEs [6]. However, their ef-
fect on the nature of reports is unclear. Barber and
Santanello [7] found that only what patients considered
more bothersome was reported spontaneously when
compared to use of a checklist of possible events. This
suggests that spontaneously reported AEs may be more
clinically meaningful, and supports concerns that de-
tailed methods produce ‘noise’: clinically irrelevant AEs
that cannot be distinguished from background rates [6,8]
Wernicke et al. [9] have also proposed that spontaneous
reporting provided larger drug-placebo differences more
often than solicitation. There is a dearth of research about
methods for the elicitation of previous or concomitant
medications in trials, despite evidence that participants fail
to report use of other antimalarials when asked [10].
A major challenge in determining the best way to elicit
these data is the lack of a gold standard to assess validity
of responses; an absolute measure of what patients experi-
ence is likely unachievable. However, in other areas of
pharmacoepidemiology, including case–control or cohort
studies and administrative databases, there has been meth-
odological investigation regarding the accuracy of self-
reported past medical conditions and treatments, through
comparison with medical or prescription records [11]. In
those contexts, recall of medical history appears dep-
endent on the type of condition, its perceived importance
and a willingness to share information. Pattern of use is
influential in recall of past medications, and indication- or
medication-specific questions increase prevalence esti-
mates compared to open-ended questions [12].
Factors that shape reporting of beneficial or adverse
effects of pharmacotherapy is a poorly researched area
[13], although a variety of relevant factors have been
proposed in different research areas. These include cul-
tural variations in how health issues are perceived [14];
negative emotions [15]; beliefs about the medication
[16]; response-shift, whereby ill health is not viewed as
such anymore [17]; and gender or language differences
that impede communication between patients and health
workers [18-20]. Belief that drugs must cause certain
[side] effects as part of the therapeutic process may also
play a role [21]. Specifically within the trial context it
has been proposed that there may be fear of lack of con-
fidentiality, stigma or negative repercussions as a result
of reporting AEs [3,22]. Nocebo effects (harmful re-
sponse to an inactive product) may be related to infor-
mation about anticipated effects given to participants
during the consent process [23,24].
This study aimed to identify factors shaping reports of
medical histories, AEs and previous or concomitant medi-
cations by participants who had malaria and/or HIV and
were enrolled in trials of concomitant antiretroviral (ARV)
and antimalarial treatments. This is to inform elicitation
practices for improving reporting in these clinical con-
texts. The ACT Consortium [25] is a global research part-
nership aiming to answer key questions on the delivery of
artemisinin-based combination therapy (ACT) for the
treatment of malaria. The Consortium involves a number
of projects that elicit safety data from trial participants,
providing an opportunity to investigate factors influencing
data in areas where, due to high rates of illiteracy, it would
be challenging to use self-completed questionnaires. This
methodological study was nested in two open-label anti-
malarial and antiretroviral interaction trials (referred to as
parent trials hereafter) that both aimed to assess the safety
and blood drug concentrations (pharmacokinetics) of the
widely-used antimalarial drug, artemether-lumefantrine
(AL). The two different study designs and contexts pro-
vided an opportunity to explore the influence of a variety of
factors on reporting. A small South African trial investi-
gated the use of AL in HIV-infected volunteers, while a
larger Tanzanian trial investigated AL in patients infected
with malaria and/or HIV.
Methods
Study design and objectives
This was a mixed method study. Parent trial participants
were asked about ill health and treatment use (in order to
record AEs, concomitant medicines and medical history)
through a variety of elicitation methods: general enquiries,
checklists, in-depth interviews and focus group discus-
sions. The primary objectives were to explore qualitatively
participants’ experiences of illness and treatment, their
reporting behaviours, and their responses to different ques-
tioning methods. Trial clinicians’ experiences with eliciting
and recording participant-reported data were also explored
for their perspective on these interactions. Secondly, the
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study aimed to compare the number and nature of data
obtained through use of different question methods. It was
assumed that the parent trials should seek medical history
data sufficient to determine eligibility and inform the caus-
ality assessment of AEs. In addition, they should detect
changes in health or treatment use from baseline such that
within-trial or pooled statistical analyses could establish
signals for, or evidence of harm or poor tolerability, or ro-
bust evidence for the absence of harm within the study
population.
Study population
The study population was participants and trial clinicians
involved with the 2 ACT Consortium parent trials. In South
Africa, this was 18 trial participants between November
2009 and February 2010, in Tanzania, 80 of 832 trial partici-
pants between October 2010 and May 2011.
Both trials investigated responses to AL, although with
different designs and participant populations. The South
African site was an urban tertiary hospital serving a
socio-economically diverse population. In this pharma-
cokinetic and safety trial, groups of otherwise healthy
HIV positive volunteers were recruited and admitted for
4 days to a pharmacology research ward. Prior to this,
participants had been followed-up after a single dose of
AL. At the time of this nested study they were returning
for a multiple-dosing period of AL twice daily for 3 days,
which involved intensive pharmacokinetic sampling
(to determine drug levels of AL), plus follow-up on an
outpatient basis until Day 21. The Tanzanian site was a
rural district hospital serving a predominantly very poor
population. In this efficacy, safety and pharmacokinetic
trial, HIV positive or negative patients presenting with
malaria symptoms were recruited from routine clinics and
attended trial consultations individually as out-patients
until Day 42. Those positive for malaria received the same
6-dose AL regimen as for South Africa, while those testing
negative were managed according to their alternative
diagnosis.
In both sites, participants who reported additional in-
formation in response to checklist questioning compared
with a general enquiry were eligible to participate in in-
depth interviews and subsequent focus group discussion.
This was to explore their disparate responses to different
questioning methods. Trial clinicians from both sites
were also invited to a focus group discussion once the
nested study was complete.
Elicitation methods
Three elicitation methods were compared sequentially: gen-
eral enquiry, check list and in-depth interview. The general
and checklist enquires were conducted on the same day at
the baseline and a follow-up visit; the in-depth interviews
were conducted within a week of the follow-up visit.
General enquiry
General open-ended questions (without reference to par-
ticular conditions, body system or medications) about
health and treatment use at baseline and follow-up visits
were routine in both trials. At the first visit, medical and
treatment histories were obtained using open ended
questions. However, as the South African participants
were returning for a second dosing period, these were
recorded in the trial files as AEs and concomitant medi-
cations, unless they pre-dated the parent trial. Responses
were probed according to common clinical practice in
eliciting a medical and treatment history, which is based
on the opinion of the enquirer regarding what further
details would be required.
Checklists
At the first visit and a follow-up visit (3 to 7 days post
enrolment), the general enquiry was immediately fol-
lowed with a checklist of questions asked by the trials’
staff focusing on body systems, symptoms, diseases and
treatments. A majority of fields in the checklists were
common to both trials (Additional file 1) although they
could not be harmonised fully. This should not have
affected this study, with its primary focus on the experi-
ence of differential reporting rather than validity of the
question methods. Data reported for the first time in
response to checklists were probed as for the general en-
quiry, and recorded in separate fields so that it was clear
which question method detected which data.
In-depth interviews
Of those participants who reported additional information
in response to the checklist compared to the general en-
quiry, a convenience sample was invited to an in-depth
interview to explore their disparate responses (described
below). These interviews also provided an opportunity to
elicit further relevant trial data using a prompted narrative
of the participant’s trial experience, reflection on previous
ill health and treatments, and photographs of typical over-
the-counter and traditional medicines available to the
study populations. These data could then be compared
with data from the other elicitation methods.
Evaluation of reporting behaviours and elicitation
methods in context
Qualitative experiences of trial participants were ex-
plored through in-depth interviews and focus group
discussions.
In-depth interviews
Twenty-seven participants who reported additional in-
formation in response to the checklist elicitation method
compared to general enquiries were invited to partici-
pate in an in-depth interview. The informed consent
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document explained that the interviewer would talk
about participants’ experiences of their health and use of
treatments but not that the interviews were specifically
looking to explore differences in reporting. The inter-
views lasted one to two hours and were conducted away
from the trial venue by a local qualitative researcher
who understood concepts relating to collecting trial
safety data. After attempting to discover further relevant
data using the narrative method described above, partici-
pants were asked for help in exploring why their report-
ing differed by question method, with reference to their
own trial data and reports.
Focus group discussions
The same participants who had participated in the in-
depth interviews were invited to participate in a focus
group discussion within a month of completing the par-
ent trial. The rationale for using focus group discussions
was the expectation that further information about the
same concepts may be revealed after reflection in a group
context. In addition, unlike the in-depth interviews, infor-
mation from focus group discussions could not influence
their ongoing trial participation, therefore participants
may have felt more comfortable talking about particular
information that they had chosen not to report during the
trial. Two focus group discussions were held in each
country. For each (with four to eight participants, sepa-
rated by HIV status to encourage openness) the facilitator
explored treatment use, the meaning or importance of
AEs, barriers to reporting and recommendations for im-
proving accuracy and completeness of clinical trial data.
One focus group discussion was also held with the trial
clinicians from both parent trials in March 2011. Topics
included the appropriate level of data elicitation needed
for adequate assessment of harm and tolerability, the rela-
tive merits of questioning methods, hypothesised barriers
to accurate reporting, and suggestions for improvement.
Question guides for the participant in-depth interviews
and focus group discussions were piloted and developed
iteratively as data emerged. Tanzanian question guides
were translated into Kiswahili using a forward-backward
translation from English. EA led South African discus-
sions in English, assisted by English-isiXhosa or Shona
speaking social scientists depending on participants’
home languages. Tanzanian discussions with trial partici-
pants were conducted in Kiswahili by AM and IM. EA
and AM conducted the focus group discussion with trial
clinicians in English.
Data management and analysis
AEs, medical histories and medications elicited from
participants in the sampling frame, including additional
reports from those who attended in-depth interview,
were described statistically by elicitation method. The
nature of reports was considered in relation to trial eligi-
bility for medical and concomitant medication histories,
and severity for AEs. Audio recordings of the interviews
and focus group discussions were transcribed in the ori-
ginal language (English, isi-Xhosa or Kiswahili), trans-
lated into English where necessary, checked for quality
and imported into NVivo 8 (QSR International, 2009)
with summaries and observations written by inter-
viewers directly after each interview. Transcripts were
analysed thematically in terms of explanations given for
differential reporting by question method, and how par-
ticipants expressed themselves. Relevant text was exam-
ined by EA for repeating ideas, which were labeled and
grouped into themes reflecting the underlying meaning
or concepts behind statements [26,27]. The emerging
coding structure was revised after each transcript, with
on-going review by CC. EA and CC explored the emer-
ging themes in relation to broader theories.
Ethical considerations
Approval was obtained from the ethics committees of the
University of Cape Town, Faculty of Health Sciences and
the Tanzanian National Institute of Medical Research Co-
ordinating Committee. Trial participants were told who
would have access to their responses and that refusal to
participate was without disadvantage for subsequent care
or place in the parent trial. Informed consent processes and
forms were available in English and local languages. Trans-
port reimbursement and refreshments were provided at in-
terviews and focus group discussions.
Results
Study participants
The characteristics of participants who were asked both
general and checklist enquiries and the subgroup who
took part in the in-depth interviews (and subsequent focus
group discussions) are given in Table 1. None of the par-
ent trial participants who were approached refused an in-
depth interview; however some interviews could not be
scheduled due to participant or interviewer availability.
Safety data reports by elicitation method
Of the 18 South African parent trial participants, 16
attended both study visits, of whom 15 (94%) reported
differently between the general enquiry and checklists.
Of 80 Tanzanian parent trial participants in the trial at
the time of the nested study, 76 attended both study
visits, of whom 65 (86%) reported differently between
the general enquiry and checklists. For practical reasons
the final sample size of those who participated in in-
depth interviews were 11 in South Africa and 16 in
Tanzania. Table 2 summarises the reports of adverse
events, medical histories and concomitant medications
elicited by question method.
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There was an overall cumulative increase in number
of reports from general enquiry, through checklists, to
in-depth interviews with the largest increase in reports
found in the checklists when compared with the general
enquires. All additional AEs reported through use of the
checklists or in-depth interview were rated as mild and
unlikely to be related to the trial drug by trial staff; and
no additional medical history or medications detected in
using those methods changed eligibility for the trials.
While there were large differences in the numbers of
reports between the trial sites, it is not informative to
make a direct comparison as, apart from the four-fold
difference in sample sizes, the type of participant and
trial designs were different. It is to be expected that
otherwise healthy HIV-positive volunteers in South Africa
have significantly fewer medical history reports compared
to those in Tanzania who were presenting with multiple
malaria symptoms; the South Africans could also report
more AEs as they had a second opportunity to do so.
In the more detailed description of data reports
(Additional file 2 and Additional file 3) it was observed
that, in particular, baseline symptoms of nausea and
vomiting in Tanzania appeared to be under-reported
until they were specifically asked about. Similarly, body
pain and fatigue were not reported until after specific
questioning. However, this may be because they were
captured within other terms (e.g. tingling or painful
sensation, abdominal pain, chest pain, muscle pain and
joint pain for body pain, and weakness for fatigue) in
the Tanzanian questioning tool. Night sweats may have
been reported within the concept of fever.
Results from the trial participants’ narratives
The qualitative data revealed that experiences of their
health or use of treatments become data through a process
including participants' recognising the information required,
considering a reply, and effective articulation, or naming,
of the response (Figure 1). The underlying social contexts
could help to explain how specific barriers and facilitators
to participant reporting manifest in these trial sites.
Factors shaping participant reporting of health and
treatments
Memory When discussing discrepancies between their
responses to the different questioning (elicitation)
methods, participants often said they forgot to report
things in response to the general enquiry and, to a min-
imal extent, the checklist. Minor, intermittent and resolved
health issues were more likely to be forgotten compared
to those more severe, persistent or current. There were no
Table 1 Characteristics of trial participants
All participants from the sampling frames Subgroup of participants interviewed
South Africa (n = 18) Tanzania (n = 80) South Africa (n = 11) Tanzania (n = 16)
Number (%) female 13 (72.2) 53 (66.3) 8 (72.7) 9 (56.3)
Median (IQR) age in years 37.1 (33.4 - 39.7) 40 (32.0 – 36.5) 38.1 (35.0 – 42.1) 34.5 (24.5 – 48.5)
Number (%) HIV positive 18 (100.0) 69 (86.3) 11 (100.0) 10 (62.5)
Number taking ARVs 18 (100.0) 63 (78.8) 11 (100.0) 9 (56.3)
Highest education
completed number (%)
Data not available for South Africa Unknown for 1 participant in South Africa
None/incomplete primary 26 (32.5) 0 6 (37.5)
Primary school 53 (66.3) 3 (27.3) 10 (62.5)
Secondary school 1 (1.3) 4 (36.4) 0
Higher education 0 3 (27.3) 0
Table 2 Summary of trial participants’ reports elicited by question method
South Africa Tanzania
Medical
histories
Adverse
events
Treatments Medical
histories
Adverse
events
Treatments
Number of reports by general enquiry* 4 23 17 285 6 196
Additional number of reports by checklists (% change from
general enquiry)*
8 (100.0) 20 (87.0) 23 (135.3) 245 (86.0) 1 (16.7) 2 (91.3)
Additional number of reports by interview **(% change from
general enquiry and checklist)
4 (33.3) 1 (2.3) 4 (10.0) 15 (2.8) 0 (0) 9 (4.5)
*All participants in the sampling frame attending both visits (South Africa n = 16, Tanzania n = 76).
**Subset of participants who took part in in-depth interviews (South Africa n = 11, Tanzania n = 16).
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consistent categories of treatments recalled more easily,
except for ARVs, which could never be forgotten as they
are considered so important to sustaining health:
“I only used it [diclofenac, an anti-inflammatory] to
reduce the tooth pain. When the pain stopped I [forgot]
them. But with these ones [ARVs] I have no time to
[forget] them, maybe God takes my spirit [fear of ill
health/death from non-adherence]” [In-depth
interview (IDI) 11, Tanzania].
Participants predominantly attributed forgetting to report
to the burden of having too much to remember, although
two South Africans said it was due to significant memory
decline since starting ARVs. The detail of the checklist, and
to some extent the in-depth interview, was strongly viewed
as helpful in overcoming memory problems.
Significance to participants When faced with a general
enquiry, participants in both sites described conscious
decisions to report current medical histories and AEs
that were more bothersome, severe or persistent as op-
posed to those experienced as intermittent or less severe.
Several South African participants also described deci-
sions to first spontaneously report a new deterioration
in health during the trial only when the symptoms wors-
ened further. South African participants often recounted
medical history in relation to when they initiated ARVs,
when health was at a low point from AIDS-related ill-
ness or initial side-effects. Illnesses experienced since
this period (major or minor) were commonly under-
reported,
“Ever since 2006 I don’t want to lie but I don’t feel
anything… I always just get sick like ordinary people”
[IDI 4, South Africa].
This extended into reporting about AEs during the
trial period, with declarations of good health followed by
mention of health issues “No, I was not sick at all. Just
only coughing, flu, only that” [IDI 8, South Africa].
Participant definitions or normalising of ill-health in-
fluenced when and how they revealed information in the
in-depth interview. Categorising illness as ‘major’ or
‘bad’ was frequently associated with hospitalisation; tu-
berculosis treated as an outpatient was not being ‘badly
sick’, and only revealed in response to a specific question
about tuberculosis. One participant did not mention her
blindness in one eye until specifically asked.
Non-significance amongst Tanzanian participants some-
times reflected a slightly different concept. Rather than re-
lating to classification of an experience as ‘normal’ and
therefore not reported, participants seemed to shape their
perception of significance more around expectations of
what would be significant to the doctor. When asked
about symptoms by way of a general enquiry, those
deemed the main problem(s) were chosen with expect-
ation that others would be treated by default:
I don’t think that you can tell the doctor one part after
another that is in pain. … But you may decide to tell
him the basic problem, or what is making me more sick.
If I tell the doctor that I have fever he might give me the
medicine … then all that I am feeling will calm down
[Focus group discussion (FGD) 1 Tanzania respondent 5].
Trial context
In-patient 
volunteers
Sick out-
patients
Underlying social factors
Trial citizenship
Deferred 
responsibility
Barriers and facilitators
Memory 
Significance to participants         
Relevance to report     
Consequences          
Articulating a response        
The blood tells everything
Question method
HEALTH OR 
TREATMENT-TAKING 
EXPERIENCE
REPORT
Recognition
Consideration
Naming
Figure 1 Diagram of trial participants’ narrative responses.
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Treatment use phraseology meanwhile revealed a hier-
archy; after ARVs or antimalarials, use of intermittent or over
the counter substances (such as painkillers or vitamins) were
mentioned, but qualified with ‘only’ or ‘apart from’. These
perceptions of significance may intersect with the next factor
shaping reporting behaviour: relevance to report.
Relevance to report Participants appeared to delay
reporting experiences that they perceived irrelevant, with
the checklists helping them to decide what was necessary.
Manifestation of relevance to report was, largely, different
between sites. In South Africa, decisions to report were
sometimes related to the trial’s objectives, i.e. whether the
information would contribute to the success of the trial:
“If I say after drinking the tablet I felt weak and tired
… then they will write it … [as] the effects of the
tablet. [To] them it gives …the wrong impression” [IDI
5 South Africa].
History of sexual dysfunction, and poor memory (not on
the checklists), were only revealed in the in-depth inter-
view by two participants, who described these as irrelevant
to the trial, and also untreatable, and therefore not useful
to report. In Tanzania, relevance was chiefly attributed to
the medical context. If a symptom at baseline was consid-
ered by the participant to be due to something other than
malaria, such as work-related activities, it might not have
been reported unless specifically prompted for. Similarly,
if medication was bought for something other than mal-
aria there was no reason to report:
“I thought because I purchased it [pain killer] by myself
because of the tooth pain I had no reason of telling him.
But the Fansidar I purchased, I had a reason of telling
him, because I can be tested and seen with malaria
again. So they’ll understand, after the Fansidar being
useless, what [they should] do” [IDI 11 Tanzania].
Consequences – attempts to control a situation Par-
ticipants in both sites described themselves or others in
the trial withholding information in response to general
questions and checklists for fear of negative conse-
quences. These negative consequences were starkly dif-
ferent between sites. In South Africa, participants feared
exclusion from the trial; there were three explicit, inde-
pendent, second-hand reports of self-treatment with lax-
atives, non-adherence with ARVs, and gastro-intestinal
illness that were withheld for this reason. When such sce-
narios were presented during the focus group discussion,
participants denied that this happened, saying that misre-
porting could undermine the trial’s objectives. In contrast,
Tanzanians considering consequences of reporting (or not)
did not mention the trial; they were worried about going
against hospital ‘rules’. One said she did not report an
anti-inflammatory taken during the trial for this reason.
Most discussion on this topic in Tanzania, however, was
in the focus group discussions and concerned fear of
reporting traditional medicines:
We who are living with [HIV], .. we are highly advised
to refrain from traditional medicine issues because
there is a difference between traditional medicines and
these drugs. ….Yesterday I felt ill and went to dig
muarobaini [neem tree root used for malaria] but
without feeling any relief after drinking it. If I come to
[doctor] today and he asks me what kind of medicine
you used yesterday, telling him muarobaini….I must
lie because already that is wrong. …That is due to fear
of telling the doctor because we were already prohibited
that thing. …There is some sort of [difficulty] telling the
truth though it’s true, but the truth remains within me.
[FGD 1 Tanzania, respondent 3].
Articulating a response South African participants,
who generally did not take long-term medications apart
from ARVs, appeared to have a small personal formulary of
named over-the-counter medications, but names of ad-hoc
prescription medications were largely unknown. Though
literate, one man displayed little interest in knowing what
his prescription was. By contrast they had impressive de-
tailed knowledge of their previous and current ARV regi-
mens. In Tanzania, names of prescription medicines,
including ARVs, were not known. As for HIV itself, ARVs
were mentioned euphemistically, even when reverence ap-
peared as high. In focus group discussions, Tanzanian par-
ticipants initially cited their lack of education and an
inability to read English labels, though it became clear that
names of ARVs and other long-term prescription medicines
are seldom verbalised during prescribing and dispensing.
Meanwhile, equally complex names of antibiotics and anti-
malarials are known, because they are talked about in
public.
Respondent: But I have not kept those [ARVs] in my
mind. I have their container but I have never read it.
Interviewer: How come you knew amoxycillin?
Respondent: [laughs] They are simple to pronounce
Interviewer: How did you get that name?
Respondent: Because they are mentioned in the
streets … like aspirin, simple names.
[IDI 4 Tanzania].
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The blood test tells doctors everything they need to
know When South African participants narrated what
happened in the trial, this was largely about blood tests
and examinations, with little mention of the verbal dis-
cussion with the clinician until they were prompted.
While this could relate to the numerous blood samples
taken in the trial ward and knowledge about the trial’s
pharmacokinetic objectives, it persisted in their descrip-
tions of follow-up visits, when tests were far fewer.
When asked about the relative importance of blood tests
versus being asked about their health and use of medi-
cines, several declared the former as equivalent or
superior.
“[The test is] like they are asking about your health. … it’s
the same thing” [FGD 01 South Africa respondent 01].
Others said blood could reveal non-adherence to
ARVs and use of any substance, including traditional
medicines. Tanzanian participants did not display such
a marked pattern, possibly because they expected to be
asked about malaria symptoms and what antimalarials
they had tried in order to inform treatment. However,
when questioned about the importance of blood tests
versus being asked about their health and use of medi-
cines their discourse reflected that the former were con-
sidered a far superior source of information for the
doctor. One participant indicated that questions were
asked merely for the doctor to identify the more import-
ant test required.
Social context of the trials
While there may also be influence from psychological fac-
tors, conversations with participants in this study reveal
social constructs that may underpin reporting behaviour.
A minor construct “Being a subject” was common to both
sites, though much stronger in South Africa; participants
indicated they were beholden to certain trial-dictated be-
haviours, mostly regarding concomitant medication use.
However, two more dominant constructs, “Trial citizen-
ship” and “Deferred responsibility” may explain some of
the differences observed between the sites.
Trial citizenship in South African inpatient volunteers
South African participants described their important
role, indeed sometimes their work, in facilitating the
trial’s success. They were largely knowledgeable of,
and aligned their work as trial participants with, re-
searchers’ objectives. On hearing a participant was
withdrawn due to a contra-indicated medication pre-
scribed by her own doctor, they felt she was correct
in reporting it even though she could not play her
trial role anymore:
Interviewer: So, how did you feel about [another
participant being withdrawn from the trial for taking
a contra-indicated medication]?
Respondent 3: We feel bad
Respondent 5: We feel very bad
Respondent 4: But [on] Saturday, the doctor told us
[about] the side-effect [of] the tablets that the girl was
taking for the skin. It will affect what? [Respondent 2:
kidneys]. ... Then [that] girl, she can’t work with us.
[FGD 02 South Africa].
Even though participants conveyed this sense of re-
sponsibility towards the integrity of the trial, there
were second-hand reports of others not playing their
role properly, deliberately withholding information for
fear of being withdrawn. Though loss of reimburse-
ment was cited as a reason for this, one participant
expressed it in relation to a worry about having to leave
because participants had “come [to] enjoy the trial”
[IDI South Africa, respondent 11]. This South African
trial was conducted under stricter conditions than the
trial in Tanzania in terms of, for example, admission
for intensive pharmacokinetic sampling periods, and
the foods and concomitant medications allowed. Be-
ing with each other and the staff for 72 hours offered
a liberating experience; there was much mention of
the opportunity to speak freely with others who
understood what it meant to be HIV positive, phone
numbers were swapped and focus group discussions
were happy reunions. This may have nurtured the
trial citizenship underpinning some decisions regard-
ing relevance to report, which were sometimes made
by consensus. Thus, for instance, an AE was consid-
ered unrelated to the South African trial if others
were not experiencing it:
“Somebody will wake up and say ‘Guys I am feeling
this, is anyone feeling it?’ And then because that one
said no… you will also think ‘Ah maybe it’s me. It’s
only me” [IDI South Africa, respondent 05].
Over and above these participants’ roles in this trial,
however, there was recognition that they were moni-
tored to avoid personal risk. Perhaps in addition to trial
citizenship, the fact that the antimalarial trial drug was
being used experimentally in participants without mal-
aria meant that they had a heightened vigilance for pos-
sible side-effects:
“I was busy trying to look for side-effects from the
trial.” [FGD 01 South Africa respondent 4] “They
Allen et al. BMC Medical Research Methodology 2013, 13:140 Page 8 of 13
http://www.biomedcentral.com/1471-2288/13/140
asked me how did I feel.. and what the medicine [did]
to me” [FGD 02 South Africa, respondent 3].
Deferred responsibility in sick Tanzanian outpatients
In Tanzania, particularly in the in-depth interviews,
there was little discussion, or sometimes understand-
ing, of the trial. Some participants showed how the
locus of responsibility for knowing relevant informa-
tion fell with trial staff as clinicians, rather than with
themselves; the doctor had the knowledge to prompt
them to reveal whatever additional information was
required over and above what they respond to a
general enquiry:
“So I think the doctor understands more, that’s why he
went on to probe. So I didn’t forget or wasn’t careless,
but it’s my knowledge that is low, that if the stomach
aches then even diarrhoea may be there, ‘what about
diarrhoea?” [FGD 1 Tanzania, respondent 1].
Tanzanian participants were recruited to the trial indi-
vidually when they presented to routine services with
malaria symptoms for which they sought a cure. The
trial was largely incidental to them achieving good
health. There were few references to researchers’ prior-
ities; it was personal:
“I didn’t just join because of the name malaria, no.
But it’s because there are tests and examinations
that are being done on me so as to know how my
health is. …So I was being researched. So I know how
my state is, I was examined” [FGD 1 Tanzania,
respondent 1].
The experience predominantly described was of feeling
ill, joining a project (to get optimal management), and
thus feeling better. Participants considered the questions
the doctor asked about health and treatments were for
their personal benefit:
“When he asked what kind of drug have you used, I
suspect that he asked so that we don’t make it a habit
buying drugs from drug shops, we should come and get
tested first” [FGD 1 Tanzania, respondent 4].
In the in-depth interview, responses to questions
about change in health since baseline overwhelmingly
concerned gratitude for improvement, malaria-related
or not.
Trial clinicians' reflections on the limits of sensitivity
Participants in both sites had overwhelmingly recom-
mended that more detailed questioning (checklists or in-
depth interviews) helped them to report, and Tanzanian
participants said that the focus group discussion taught
them the importance of maintaining their own detailed
illness and treatment record, for its personal health ben-
efits. Trial clinicians, meanwhile, spoke of the challenge
of eliciting comprehensive but relevant data when they
will never know everything. For well-studied drugs, the
focus of more detailed questioning could be on known
or anticipated risks, combined with general enquires to
detect anything else. But it was a quandary whether to
probe for AEs that are perhaps insignificant or irrelevant
to both clinicians and participants:
“If they choose not to tell me about their headache
when I’m asking them how they are and how they
[feel] in their body…how severe could it be or… how
important [is it] to them?“ [Trial clinician 2].
For trials of drugs with known safety profiles:
“Isn’t the grading such a key issue? Because people’s
lives are full of minor mishaps, and minor symptoms
all the time. And if you really, really wring it out of
people, you could generate a lot of irrelevant grade 1
stuff” [Trial clinician 4].
There was, however, concern that selective detailed
questioning could miss minor illness that impacts on ad-
herence, and thus efficacy and an increased risk of mal-
aria resistance at a population level. These clinicians,
reflecting how patients may be intimidated by their role
as doctors, despite them being at pains to be otherwise,
suggested that other cadres of staff be involved in order to
overcome barriers to reporting. This involvement, they
said, could include designing elicitation strategies (social
scientists), questioning participants (nurses or social scien-
tists) or interpreting safety results (anthropologists).
Discussion
Clinical trial guidelines have been developed to attain
common standards across phases of drug development
and disparate sites [28]. However, little is offered about
methods for questioning participants to elicit informa-
tion pertaining to harm and tolerability outcomes. The
issue of whether to employ checklists in trials, as is rou-
tine in other pharmacoepidemiological study designs,
and, if so, their components and mode of delivery, re-
mains contentious. This study shows, as others have,
that asking participants to indicate which of a checklist
of items applies to them increases the sensitivity of de-
tecting data compared to a general enquiry. In addition,
some data were only detected during subsequent in-
depth interviews, suggesting that checklists overcame
some, but not all, factors involved in under-reporting in
response to a general enquiry. In these two trials the
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additional data gained by more detailed or in-depth
questioning did not alter eligibility for participation, or
detection of AEs which staff determined to be related to
the study drug(s). However, because of the inherent limi-
tations of individual causality assessments, lost AEs may
be ADRs when analysed statistically in a pooled analysis.
The findings of this qualitative study suggest that con-
tents of a checklist cannot feasibly be exhaustive enough
to trigger all issues forgotten, deemed insignificant or ir-
relevant. It is also unlikely that checklists alone will
overcome fears of reporting, by those who perceive
themselves as either participants or patients.
Data reports in context
This study offers empiricial evidence for the impact on
antimalarial and ARV trial safety endpoints of individual
perceptions of what is (and is not) memorable, significant,
relevant, of personal consequence, articulable and neces-
sary to report. Recall was a dominant factor, reflecting the
focus on memory in the broader pharmacoepidemiological
literature about validity of participant-reported data [11].
In addition, this study provides evidence of some less-
studied influences on reporting, including participants’
perceptions of significance (whereby illness or treatment
use may be normalised or gauged against another), rele-
vance to report and negative consequences of reporting.
Such factors influencing participant reporting in clin-
ical trials are similar to those observed in other areas
of epidemiology, suggesting that the evidence base for
elicitation could be extended by learning from rele-
vant methodological work conducted in other disci-
plines [29,30].
The study also identifies factors influencing elicitation
processes and outcomes that could be more specific to
the clinical trial context. Perceptions about relevance to
report and fears of reporting appeared most likely to be
influenced by differences between the trial sites. Others
have explored how trial participants understand their
identity, as being somewhere on a continuum from pa-
tient to active volunteer, and how this may shape out-
comes [31-33]. This study describes how the South
African participants appeared to take on a form of “trial
citizenship”. Their prolonged opportunity to interact
with staff in the ward is likely to have affected their
understanding of the trial and what was important to re-
searchers in a way that differed to the Tanzanian out-
patient participants. The South African participants took
on a responsible, job-like, role in determining the trial’s
outcome. Beyond this, these otherwise healthy, HIV
positive South Africans described their experience in the
trial as a treat, a space to be free from a complicated life.
The small community of participants in the trial ward,
situated in a wider context of AIDS activism and social
mobility, may reflect active biological citizens in
allegiance with the conventional biomedical community
of clinical trial staff [34]. The Tanzanian situation, mean-
while, is more likely to have represented a typical mal-
aria therapeutic efficacy study whereby participants seek
a cure from a clinic as usual and are focused on recov-
ery. As observed elsewhere, despite consent information
detailing experimental aspects of the trial, the consulta-
tions were understood by Tanzanians largely for their
personal medical benefit [35].
Locus of responsibility for assessing causality
This study did not reveal whether the design and con-
textual differences between the two sites fully explains
the relatively high number of AEs in South Africa com-
pared to Tanzania, though it may be that there was
greater awareness of the focus on detecting side-effects
in the former trial, compared with the latter where the
focus appeared to be on resolution of malaria symptoms.
South African participants were also relatively healthy,
which may have increased their reporting of any deterior-
ation in health. If so, this signals the potential for the trial
design to influence how safety end points are understood
and reported. While individual causality assessments made
by staff during a trial allow for clinical decisions and ad-
herence to regulatory reporting timelines, a central tenet
is that evidence for causality is determined for registration
purposes on the basis of aggregated data at the end of a
trial or on meta-analysis with data from similar trials. The
findings of this study suggest that implicit assessments
of causality by participants can occur very early in the
process of data generation, undermining the assump-
tions behind the ‘objective data’ used to determine
harm and tolerability. Participants make decisions to
report based on their personal logical assessments of
causality, severity and risk-benefit. Thus, the lines be-
tween adverse events and suspected adverse drug re-
actions according to ICH definitions of causality are
blurred at the point of questioning [28].
The importance of treatment literacy
There were significant differences in how ARVs were
talked about by participants in these two sites. Treat-
ment literacy - i.e. knowing about medications one is
taking - is fundamental to pharmacoepidemiology, espe-
cially where record linkage is difficult. Yet appropriate
ways of eliciting concomitant medication reports in trials
is a particularly neglected research area. Lay public defi-
nitions of what constitutes a medication may explain ob-
served delays in reporting some medications versus
others [36], and this study’s data from Tanzania suggest
that drugs considered not relevant to the hospital are
not reported. Others have shown how people may not
know names of prescribed medications, so rather leave
this knowledge to a health practitioner [37]. This
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behaviour may be more likely in more paternalistic
healthcare systems [38]. However, HIV is a particularly
stigmatised condition, and references to it (and its treat-
ment) may also be subtle, even by providers. While
South Africans also appeared not to know names of
prescription-only drugs, their ability to intimately know
ARVs could be a result of greater progress in de-
stigmatising HIV/AIDS, particularly in a setting where
participants are likely to be empowered by well-known
advocacy groups and treatment programs [39]. Though
the Tanzanian respondents did not express themselves
as trial citizens, their usual experience of malaria man-
agement was certainly enhanced by the specialised, de-
dicated trial team. By the time of their focus group
discussions they spoke more knowledgeably about the
trial, expressed satisfaction with the focus group discus-
sion allowing them to socialise, dropped euphemisms for
HIV, and proposed they take more responsibility for
keeping health and treatment records. This suggests
there is scope for altering what could be the natural
course of a patient-health facility relationship to over-
come specific impediments to trial reporting. However,
this would need careful consideration in view of evi-
dence that moving away from usual care to the trial con-
text may influence how information that becomes safety
end points are understood and reported [40].
Blood tests versus reports
Blood taking is a strong symbol of biomedicine, and
there may be unrealistic expectations about the capabil-
ities of blood tests in trials [35]. The privileging of blood
over recounted illness and treatment experiences may
reflect the recognition of a technological imperative in
biomedicine; that tests and equipment have the power
to provide doctors with the answers they require [41].
This may be reinforced by a lack of opportunity to de-
scribe illnesses, with health workers indicating what is
important to say, hear and know [42]. If trial participants
or patients are to be encouraged to relate their experi-
ences of illnesses and concomitant medications, they
may need reassurance that their experience is of equal
importance and that blood tests may not provide the
same information. Those eliciting responses may need to
show particular patience in listening to stories that sur-
round trial data end points.
Limitations
This study does not reveal a whole ‘truth’, as participants’
recognition of, and willingness to report information
vary, and are subject to the trial clinicians' and re-
searchers’ interpretations. Other than lack of a gold
standard, a potential limitation is that participants who
did not report differently between general enquiries and
checklists were systematically different from those who
did. As the goal was to explore reasons for non-
reporting, this study focused on the latter, but future
work could include the former to understand reporting
more generally. Interviewing participants immediately
after each visit where general and checklist enquiries were
compared could have increased the validity of compari-
sons, but could also have led to participant fatigue. Thus,
it was opted to use time and budget judiciously, delaying
in-depth interviews until after Day 7. The sample size was
too small to detect statistically significant differences in re-
sponses to the 3 questioning methods and it was not pos-
sible to measure influence from other factors, such as the
characteristics of the trial clinicians and interviewers (in-
cluding role and gender), precise mode of delivery of ques-
tions, or influence from the participant trial information.
The questioning methods were compared in a sequential
design rather than in a direct parallel manner as this was a
realistic representation of how these methods are generally
used in trials. The study results may not be generalizable
to other trials where the methods to detect safety data and
context are very different.
Conclusion
This study offers more evidence that questioning methods
influence the detection of clinical trial safety data. This
could prove a major limitation to optimal safety assess-
ments, and preclude valid pooled data safety analyses. The
study offers explanations for this phenomenon through
the voices of participants, indicating that different trial
contexts cultivated some specific conditions that had a
role in mediating recognition, reporting and articulation
of important variables. Based on this work, it makes sense
to develop appropriate messages for participants to convey
the concept that checklist items, if used, are merely exam-
ples of the level of data required, and that their answers to
questions about ill health and treatment use are as import-
ant as tests and examinations. This may particularly help
those believing it is the health worker alone who assumes
responsibility for reports. Participants could also be coun-
seled to quell potential fears about reporting and appropri-
ate ways to manage prohibited concomitant medications
reports without ‘punishment’ could be explored. For any
elicitation method, conceptualisations of the purposes of
elicitation, including those that trial staff hold, should be
incorporated in its design to help negate potential areas of
mismatch. There is a need to find optimal phraseology to
ensure understanding of question terminology. In areas
with low treatment literacy, pictures or samples could help
staff uncover the names of concomitant medications. Pic-
torial methods may also be of value in enhancing commu-
nication, including the rationale for the information
needed [43]. The challenge in incorporating these in clin-
ical trials is the need to be systematic whilst being locally
interpretable. Despite their limitations, checklists are an
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obvious focus, a way forward being to explore, over and
above content, their mode of application. It is here that
consideration of possible influences from a trial’s social
context would be most useful. Clinical researchers could
also consider what role their participants may take on, for
example that of a patient or a trial citizen. Further meth-
odological work should be embedded in clinical trials to
investigate influences on the measurement of participant-
reported endpoints [44]. Understanding contextual factors
influencing trial outcomes could form the basis of innova-
tive ways to capture important safety data outcomes [45].
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